diaendoСахарный диабетDiabetes mellitus2072-03512072-0378Endocrinology research centre10.14341/DM7693diaendo-7693Research ArticleОт редакцииEditorial noteСовременные базальные инсулины: продолжение истории или начало новой эры?Modern basal insulins: an ongoing story or the start of a new era?https://orcid.org/0000-0002-8175-7886ДедовИван ИвановичDedovIvan Ivanovich

MD, PhD, Professor, Deputy president of the Russian Academy  of sciences

dedov@endocrincentr.ruФГБУ Эндокринологический научный центр Минздрава РоссииРоссияEndocrinology Research CentreRussian Federation201510112015184511Copyright © Дедов И.И., 20152015Дедов И.И.Dedov I.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.dia-endojournals.ru/jour/article/view/7693

Базальный инсулин является важным инструментом при лечении сахарного диабета (СД) как 1, так и 2 типа. Разработка аналогов инсулина улучшила возможности лечения СД. Тем не менее, несмотря на значительный прогресс в понимании физиологии, химии, кинетики и механизмов действия инсулина, имеющиеся в настоящее время препараты базального инсулина не идеально имитируют профиль эндогенного инсулина. Хотя базальные аналоги инсулина имеют ряд преимуществ по сравнению с нейтральным протамином Хагедорна (инсулином НПХ) при лечении СД, гипогликемия по-прежнему остается основной проблемой на пути достижения оптимального гликемического контроля у большинства пациентов с СД. Неудовлетворенные клинические потребности служат стимулом для продолжения поиска и разработки новых базальных аналогов инсулина с улучшенным фармакологическим профилем. В этой статье обсуждаются специфические характеристики новых длительно действующих аналогов инсулина, чтобы лучше понимать их преимущества и ограничения в управлении диабетом, а также их возможности для физиологической и безопасной заместительной инсулинотерапии.

Basal insulin represents an essential tool in the treatment of both type 1 and type 2 diabetes mellitus. The development of insulin analogues has improved the possibilities of diabetes treatment. Despite significant progress in understanding the physiology, chemistry, kinetics and action of insulin, currently available basal insulin products do not optimally mimic the endogenous profile of insulin. Although basal insulin analogues have some advantages over neutral protamine Hagedorn insulin in diabetes treatment, hypoglycaemia remains the main problem in the achievement of optimal glycaemic control in most patients with diabetes. These unmet clinical needs have stimulated the development of new basal insulin analogues with improved pharmacological profiles. This article reviews the specific characteristics of new long-acting insulin analogues to try and understand their benefits and limitations in the improvement of diabetes management and their possibilities in physiologic and safe insulin replacement.

сахарный диабетинсулинотерапияэволюция базальных аналогов инсулинадеглудекdiabetes mellitusinsulin therapybasal insulin analogues evolutiondegludecReferencesШестакова М.В. Реальная клиническая практика лечения сахарного диабета 2 типа в Российской Федерации по данным открытой проспективной наблюдательной программы «ДИА-КОНТРОЛЬ». // Сахарный диабет. – 2011. – Т. 14. – №4 – С.75-80. [Shestakova MV. Actual ambulatory care in patients with type 2 diabetes mellitus in Russian Federation according to open label prospective observational study DIA-CONTROL. Diabetes mellitus. 2011;14(4):75-80. (in Russ)] doi: 10.14341/2072-0351-5822Шестакова М.В. Реальная клиническая практика лечения сахарного диабета 2 типа в Российской Федерации по данным открытой проспективной наблюдательной программы «ДИА-КОНТРОЛЬ». // Сахарный диабет. – 2011. – Т. 14. – №4 – С.75-80. [Shestakova MV. Actual ambulatory care in patients with type 2 diabetes mellitus in Russian Federation according to open label prospective observational study DIA-CONTROL. Diabetes mellitus. 2011;14(4):75-80. (in Russ)] doi: 10.14341/2072-0351-5822Berger M. Практика инсулинотерапии / Под ред. Старостиной Е.Г., Дедова И.И. Первое русское издание. – Berlin:Springer-Verlag; 1990. [Berger M. Praktika insulinoterapii. Ed. by Starostina E.G., Dedov I.I. First Russian Edition. Berlin: Springer-Verlag; 1990. (in Russ)].Berger M. Практика инсулинотерапии / Под ред. Старостиной Е.Г., Дедова И.И. Первое русское издание. – Berlin:Springer-Verlag; 1990. [Berger M. Praktika insulinoterapii. Ed. by Starostina E.G., Dedov I.I. First Russian Edition. Berlin: Springer-Verlag; 1990. (in Russ)].Tibaldi JM. Evolution of insulin development: focus on key parameters. Advances in therapy. 2012;29(7):590-619. doi: 10.1007/s12325-012-0034-8Tibaldi JM. Evolution of insulin development: focus on key parameters. Advances in therapy. 2012;29(7):590-619. doi: 10.1007/s12325-012-0034-8Garber AJ. Restaging insulin therapy for patients with type 2 diabetes. Diabetes, obesity & metabolism. 2009;11 Suppl 5:1-5. doi: 10.1111/j.1463-1326.2009.01136.xGarber AJ. Restaging insulin therapy for patients with type 2 diabetes. Diabetes, obesity & metabolism. 2009;11 Suppl 5:1-5. doi: 10.1111/j.1463-1326.2009.01136.xHeise T, Pieber TR. Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies. Diabetes, Obesity & Metabolism. 2007;9(5):648-659. doi: 10.1111/j.1463-1326.2007.00756.xHeise T, Pieber TR. Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies. Diabetes, Obesity & Metabolism. 2007;9(5):648-659. doi: 10.1111/j.1463-1326.2007.00756.xMullins P, Sharplin P, Yki-Jarvinen H, et al. Negative Binomial Meta-Regression Analysis of Combined Glycosylated Hemoglobin and Hypoglycemia Outcomes Across Eleven Phase III and IV Studies of Insulin Glargine Compared with Neutral Protamine Hagedorn Insulin in Type 1 and Type 2 Diabetes Mellitus. Clinical Therapeutics.2007;29(8):1607-1619. doi: 10.1016/j.clinthera.2007.08.020Mullins P, Sharplin P, Yki-Jarvinen H, et al. Negative Binomial Meta-Regression Analysis of Combined Glycosylated Hemoglobin and Hypoglycemia Outcomes Across Eleven Phase III and IV Studies of Insulin Glargine Compared with Neutral Protamine Hagedorn Insulin in Type 1 and Type 2 Diabetes Mellitus. Clinical Therapeutics.2007;29(8):1607-1619. doi: 10.1016/j.clinthera.2007.08.020Monami M, Marchionni N, Mannucci E. Long-acting insulin analogues vs. NPH human insulin in type 1 diabetes. A meta-analysis. Diabetes, obesity & metabolism. 2009;11(4):372-378. doi: 10.1111/j.1463-1326.2008.00976.xMonami M, Marchionni N, Mannucci E. Long-acting insulin analogues vs. NPH human insulin in type 1 diabetes. A meta-analysis. Diabetes, obesity & metabolism. 2009;11(4):372-378. doi: 10.1111/j.1463-1326.2008.00976.xHorvath K, Jeitler K, Berghold A, et al. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. The Cochrane database of systematic reviews. 2007;(2):CD005613. doi: 10.1002/14651858.CD005613.pub3Horvath K, Jeitler K, Berghold A, et al. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. The Cochrane database of systematic reviews. 2007;(2):CD005613. doi: 10.1002/14651858.CD005613.pub3Szypowska A, Golicki D, Groele L, Pankowska E. Long-acting insulin analogue detemir compared with NPH insulin in type 1 diabetes: a systematic review and meta-analysis. Polskie Archiwum Medycyny Wewnetrznej. 2011;121(7-8):237-246.Szypowska A, Golicki D, Groele L, Pankowska E. Long-acting insulin analogue detemir compared with NPH insulin in type 1 diabetes: a systematic review and meta-analysis. Polskie Archiwum Medycyny Wewnetrznej. 2011;121(7-8):237-246.Tricco AC, Ashoor HM, Antony J, et al. Safety, effectiveness, and cost effectiveness of long acting versus intermediate acting insulin for patients with type 1 diabetes: systematic review and network meta-analysis. BMJ. 2014;349:g5459. doi: 10.1136/bmj.g5459Tricco AC, Ashoor HM, Antony J, et al. Safety, effectiveness, and cost effectiveness of long acting versus intermediate acting insulin for patients with type 1 diabetes: systematic review and network meta-analysis. BMJ. 2014;349:g5459. doi: 10.1136/bmj.g5459Koehler G, Treiber G, Wutte A, et al. Pharmacodynamics of the long-acting insulin analogues detemir and glargine following single-doses and under steady-state conditions in patients with type 1 diabetes. Diabetes, obesity & metabolism. 2014;16(1):57-62. doi: 10.1111/dom.12178Koehler G, Treiber G, Wutte A, et al. Pharmacodynamics of the long-acting insulin analogues detemir and glargine following single-doses and under steady-state conditions in patients with type 1 diabetes. Diabetes, obesity & metabolism. 2014;16(1):57-62. doi: 10.1111/dom.12178DeVries JH, Nattrass M, Pieber TR. Refining basal insulin therapy: what have we learned in the age of analogues? Diabetes/metabolism research and reviews. 2007;23(6):441-454. doi: 10.1002/dmrr.762DeVries JH, Nattrass M, Pieber TR. Refining basal insulin therapy: what have we learned in the age of analogues? Diabetes/metabolism research and reviews. 2007;23(6):441-454. doi: 10.1002/dmrr.762Garg SK, Gottlieb PA, Hisatomi ME, et al. Improved glycemic control without an increase in severe hypoglycemic episodes in intensively treated patients with type 1 diabetes receiving morning, evening, or split dose insulin glargine.Diabetes research and clinical practice. 2004;66(1):49-56. doi: 10.1016/j.diabres.2004.02.008Garg SK, Gottlieb PA, Hisatomi ME, et al. Improved glycemic control without an increase in severe hypoglycemic episodes in intensively treated patients with type 1 diabetes receiving morning, evening, or split dose insulin glargine.Diabetes research and clinical practice. 2004;66(1):49-56. doi: 10.1016/j.diabres.2004.02.008Marre M, Pinget M, Gin H, et al. Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain: 52-week data from the PREDICTIVE study in a cohort of French patients with type 1 or type 2 diabetes. Diabetes & metabolism. 2009;35(6):469-475. doi: 10.1016/j.diabet.2009.06.004Marre M, Pinget M, Gin H, et al. Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain: 52-week data from the PREDICTIVE study in a cohort of French patients with type 1 or type 2 diabetes. Diabetes & metabolism. 2009;35(6):469-475. doi: 10.1016/j.diabet.2009.06.004Investigators OT, Gerstein HC, Bosch J, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. The New England Journal of Medicine. 2012;367(4):319-328. doi: 10.1056/NEJMoa1203858Investigators OT, Gerstein HC, Bosch J, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. The New England Journal of Medicine. 2012;367(4):319-328. doi: 10.1056/NEJMoa1203858Haahr H, Heise T. A review of the pharmacological properties of insulin degludec and their clinical relevance. Clin Pharmacokinet. 2014;53(9):787-800. doi: 10.1007/s40262-014-0165-yHaahr H, Heise T. A review of the pharmacological properties of insulin degludec and their clinical relevance. Clin Pharmacokinet. 2014;53(9):787-800. doi: 10.1007/s40262-014-0165-yKorsatko S, Deller S, Mader JK, et al. Ultra-long pharmacokinetic properties of insulin degludec are comparable in elderly subjects and younger adults with type 1 diabetes mellitus. Drugs & aging. 2014;31(1):47-53. doi: 10.1007/s40266-013-0138-0Korsatko S, Deller S, Mader JK, et al. Ultra-long pharmacokinetic properties of insulin degludec are comparable in elderly subjects and younger adults with type 1 diabetes mellitus. Drugs & aging. 2014;31(1):47-53. doi: 10.1007/s40266-013-0138-0Biester T, Blaesig S, Remus K, et al. Insulin degludec’s ultra-long pharmacokinetic properties observed in adults are retained in children and adolescents with type 1 diabetes. Pediatric diabetes. 2014;15(1):27-33. doi: 10.1111/pedi.12116Biester T, Blaesig S, Remus K, et al. Insulin degludec’s ultra-long pharmacokinetic properties observed in adults are retained in children and adolescents with type 1 diabetes. Pediatric diabetes. 2014;15(1):27-33. doi: 10.1111/pedi.12116Kupcova V, Arold G, Roepstorff C, et al. Insulin degludec: pharmacokinetic properties in subjects with hepatic impairment. Clinical drug investigation. 2014;34(2):127-133. doi: 10.1007/s40261-013-0154-1Kupcova V, Arold G, Roepstorff C, et al. Insulin degludec: pharmacokinetic properties in subjects with hepatic impairment. Clinical drug investigation. 2014;34(2):127-133. doi: 10.1007/s40261-013-0154-1Kiss I, Arold G, Roepstorff C, et al. Insulin degludec: pharmacokinetics in patients with renal impairment. Clin Pharmacokinet. 2014;53(2):175-183. doi: 10.1007/s40262-013-0113-2Kiss I, Arold G, Roepstorff C, et al. Insulin degludec: pharmacokinetics in patients with renal impairment. Clin Pharmacokinet. 2014;53(2):175-183. doi: 10.1007/s40262-013-0113-2Funakoshi S, Hashiguchi J, Komine M, et al. Superior glycaemic control effects with insulin degludec (IDeg) to insulin glargine (IGlar) in diabetic hemodialysis (HD) patients assessed by continuous glucose monitoring (CG M) (63-OR).Ned Tijdschr Diabet. 2014;12(4):16-16. doi: 10.1007/s12467-014-0037-yFunakoshi S, Hashiguchi J, Komine M, et al. Superior glycaemic control effects with insulin degludec (IDeg) to insulin glargine (IGlar) in diabetic hemodialysis (HD) patients assessed by continuous glucose monitoring (CG M) (63-OR).Ned Tijdschr Diabet. 2014;12(4):16-16. doi: 10.1007/s12467-014-0037-yRatner RE, Gough SC, Mathieu C, et al. Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials. Diabetes, obesity & metabolism. 2013;15(2):175-184. doi: 10.1111/dom.12032Ratner RE, Gough SC, Mathieu C, et al. Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials. Diabetes, obesity & metabolism. 2013;15(2):175-184. doi: 10.1111/dom.12032Vora J, Christensen T, Rana A, Bain SC. Insulin degludec versus insulin glargine in type 1 and type 2 diabetes mellitus: a meta-analysis of endpoints in phase 3a trials. Diabetes therapy. 2014;5(2):435-446. doi: 10.1007/s13300-014-0076-9Vora J, Christensen T, Rana A, Bain SC. Insulin degludec versus insulin glargine in type 1 and type 2 diabetes mellitus: a meta-analysis of endpoints in phase 3a trials. Diabetes therapy. 2014;5(2):435-446. doi: 10.1007/s13300-014-0076-9Owens DR, Matfin G, Monnier L. Basal insulin analogues in the management of diabetes mellitus: What progress have we made? Diabetes/metabolism research and reviews. 2014;30(2):104-119. doi: 10.1002/dmrr.2469Owens DR, Matfin G, Monnier L. Basal insulin analogues in the management of diabetes mellitus: What progress have we made? Diabetes/metabolism research and reviews. 2014;30(2):104-119. doi: 10.1002/dmrr.2469Russell-Jones D, Gall MA, Niemeyer M, et al. Insulin degludec results in lower rates of nocturnal hypoglycaemia and fasting plasma glucose vs. insulin glargine: A meta-analysis of seven clinical trials. Nutrition, metabolism, and cardiovascular diseases. NMCD. 2015;25(10):898-905. doi: 10.1016/j.numecd.2015.06.005Russell-Jones D, Gall MA, Niemeyer M, et al. Insulin degludec results in lower rates of nocturnal hypoglycaemia and fasting plasma glucose vs. insulin glargine: A meta-analysis of seven clinical trials. Nutrition, metabolism, and cardiovascular diseases. NMCD. 2015;25(10):898-905. doi: 10.1016/j.numecd.2015.06.005Jørgensen KH, Hansen AK, Buschard K. Five fold increase of insulin concentration delays the absorption of subcutaneously injected human insulin suspensions in pigs. Diabetes Res Clin Pract. 2000;50(3):161-167. doi: 10.1016/s0168-8227(00)00196-0.Jørgensen KH, Hansen AK, Buschard K. Five fold increase of insulin concentration delays the absorption of subcutaneously injected human insulin suspensions in pigs. Diabetes Res Clin Pract. 2000;50(3):161-167. doi: 10.1016/s0168-8227(00)00196-0.Korsatko S, Deller S, Koehler G, et al. A comparison of the steady-state pharmacokinetic and pharmacodynamic profiles of 100 and 200 U/mL formulations of ultra-long-acting insulin degludec. Clinical drug investigation. 2013;33(7):515-521. doi: 10.1007/s40261-013-0096-7Korsatko S, Deller S, Koehler G, et al. A comparison of the steady-state pharmacokinetic and pharmacodynamic profiles of 100 and 200 U/mL formulations of ultra-long-acting insulin degludec. Clinical drug investigation. 2013;33(7):515-521. doi: 10.1007/s40261-013-0096-7Gough SC, Bhargava A, Jain R, et al. Low-volume insulin degludec 200 units/ml once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-target trial: the BEGIN LOW VOLUME trial. Diabetes care. 2013;36(9):2536-2542. doi: 10.2337/dc12-2329Gough SC, Bhargava A, Jain R, et al. Low-volume insulin degludec 200 units/ml once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-target trial: the BEGIN LOW VOLUME trial. Diabetes care. 2013;36(9):2536-2542. doi: 10.2337/dc12-2329Steinstraesser A, Schmidt R, Bergmann K, et al. Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml. Diabetes, obesity & metabolism. 2014;16(9):873-876. doi: 10.1111/dom.12283Steinstraesser A, Schmidt R, Bergmann K, et al. Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml. Diabetes, obesity & metabolism. 2014;16(9):873-876. doi: 10.1111/dom.12283Becker RH, Dahmen R, Bergmann K, et al. New insulin glargine 300 Units. mL-1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 Units. mL-1. Diabetes care. 2015;38(4):637-643. doi: 10.2337/dc14-0006Becker RH, Dahmen R, Bergmann K, et al. New insulin glargine 300 Units. mL-1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 Units. mL-1. Diabetes care. 2015;38(4):637-643. doi: 10.2337/dc14-0006Ritzel R, Roussel R, Bolli GB, et al. Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes.Diabetes, obesity & metabolism. 2015;17(9):859-867. doi: 10.1111/dom.12485Ritzel R, Roussel R, Bolli GB, et al. Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes.Diabetes, obesity & metabolism. 2015;17(9):859-867. doi: 10.1111/dom.12485Home PD, Bergenstal RM, Bolli GB, et al. New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4). Diabetes care. 2015;38(12):2217-2225. doi: 10.2337/dc15-0249.Home PD, Bergenstal RM, Bolli GB, et al. New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4). Diabetes care. 2015;38(12):2217-2225. doi: 10.2337/dc15-0249.Дедов И.И., Шестакова М.В., Галстян Г.Р., и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под редакцией И.И. Дедова, М.В. Шестаковой (7-й выпуск). // Сахарный диабет. – 2015. – Т. 18. – №1S. – С.1-112. [Dedov II, Shestakova MV, Galstyan GR, et al. Standards of specialized diabetes care. Edited by Dedov I.I., Shestakova M.V. (7th edition). Diabetes mellitus. 2015;18(1S):1-112. (in Russ)] doi: 10.14341/DM20151S1-112Дедов И.И., Шестакова М.В., Галстян Г.Р., и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под редакцией И.И. Дедова, М.В. Шестаковой (7-й выпуск). // Сахарный диабет. – 2015. – Т. 18. – №1S. – С.1-112. [Dedov II, Shestakova MV, Galstyan GR, et al. Standards of specialized diabetes care. Edited by Dedov I.I., Shestakova M.V. (7th edition). Diabetes mellitus. 2015;18(1S):1-112. (in Russ)] doi: 10.14341/DM20151S1-112

The authors declare that there are no conflicts of interest present.